close 73% van de retail rekeningen verliezen gelden met de handel in CFD`s bij deze aanbieder. Investeringen zijn risicovol en zijn niet geschikt voor alle beleggers. CFD`s zijn complexe instrumenten met een hoog risico om snel gelden te verliezen vanwege het hefboomeffect. 73% van de retail beleggers lijdt verlies bij het handelen in CFD`s met deze aanbieder. Het is belangrijk dat u goed begrijpt hoe CFD`s werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
ZoekenZoeken
Change languageNederlands
Dashboard
Home・Aandelen Lijst・Virbac SA
Search

Virbac SA

Open

SectorGezondheidszorg

354 -0.56

Buy

Prijsupdate 31 dec 2025, 12:54 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

354

Max

355

Belangrijke statistieken

By Trading Economics

Inkomsten

82M

Verkoop

738M

K/W

Sectorgemiddelde

22.544

88.032

Dividendrendement

0.41

Winstmarge

11.162

Werknemers

6,365

EBITDA

157M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+9.82% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.41%

2.26%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

3B

Vorige openingsprijs

354.56

Vorige sluitingsprijs

354

Nieuwssentiment

By Acuity

67%

33%

331 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

303.6 / 306.25 Steun & Weerstand

Virbac SA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

31 dec 2025, 22:20 UTC

Belangrijke Marktbewegers

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

DJ

Lezen

31 dec 2025, 17:31 UTC

Belangrijke Marktbewegers

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

DJ

Lezen

31 dec 2025, 16:30 UTC

Belangrijke Marktbewegers

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

DJ

Lezen

31 dec 2025, 15:19 UTC

Belangrijke Marktbewegers

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

DJ

Lezen

31 dec 2025, 15:17 UTC

Belangrijke Marktbewegers

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

DJ

Lezen

31 dec 2025, 14:37 UTC

Belangrijke Marktbewegers

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

DJ

Lezen

31 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

DJ

Lezen

31 dec 2025, 21:13 UTC

Acquisities, Fusies, Overnames

10 People to Watch in Wealth Management in 2026 -- Barrons.com

DJ

Lezen

31 dec 2025, 20:40 UTC

Marktinformatie

Dollar Posting Its Worst Year Since 2017 -- Market Talk

DJ

Lezen

31 dec 2025, 20:22 UTC

Marktinformatie

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

DJ

Lezen

31 dec 2025, 19:50 UTC

Marktinformatie

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

DJ

Lezen

31 dec 2025, 19:31 UTC

Marktinformatie

Precious Metals Cap Off Record Runs -- Market Talk

DJ

Lezen

31 dec 2025, 18:50 UTC

Marktinformatie

Global Equities Roundup: Market Talk

DJ

Lezen

31 dec 2025, 18:50 UTC

Marktinformatie

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

DJ

Lezen

31 dec 2025, 17:17 UTC

Marktinformatie

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

DJ

Lezen

31 dec 2025, 17:16 UTC

Belangrijke Marktbewegers

OwlTing Climbs on Launch of $10M Stock-Buyback Program

DJ

Lezen

31 dec 2025, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

DJ

Lezen

31 dec 2025, 17:00 UTC

Acquisities, Fusies, Overnames

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

DJ

Lezen

31 dec 2025, 15:57 UTC

Acquisities, Fusies, Overnames

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

DJ

Lezen

31 dec 2025, 15:54 UTC

Marktinformatie

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

DJ

Lezen

31 dec 2025, 15:02 UTC

Belangrijke Marktbewegers

Nike Shares Rise After CEO Hill Buys $1M of Shares

DJ

Lezen

31 dec 2025, 14:40 UTC

Acquisities, Fusies, Overnames

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

DJ

Lezen

31 dec 2025, 14:20 UTC

Marktinformatie

Crude Futures On Track to End the Year With Losses -- Market Talk

DJ

Lezen

31 dec 2025, 13:46 UTC

Marktinformatie

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

DJ

Lezen

31 dec 2025, 13:01 UTC

Winsten
Acquisities, Fusies, Overnames

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

DJ

Lezen

31 dec 2025, 11:10 UTC

Marktinformatie

Copper Remains in Touching Distance of Record Highs -- Market Talk

DJ

Lezen

31 dec 2025, 10:46 UTC

Marktinformatie

Euro on Track For Strong Annual Performance -- Market Talk

DJ

Lezen

31 dec 2025, 10:25 UTC

Marktinformatie

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

DJ

Lezen

31 dec 2025, 10:23 UTC

Marktinformatie

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

DJ

Lezen

31 dec 2025, 09:33 UTC

Marktinformatie

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

DJ

Lezen

Virbac SA Prognose

Koersdoel

By TipRanks

9.82% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 391.5 EUR  9.82%

Hoogste 415 EUR

Laagste 368 EUR

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Virbac SA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

1

Buy

1

Hold

0

Sell

Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan Virbac SA - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

303.6 / 306.25Steun & Weerstand

Korte Termijn

Bearish Evidence

Recent bearish events outweigh bullish events.

Gemiddeld Termijn

Very Strong Bullish Evidence

All events are bullish.

Lange Termijn

Weak Bearish Evidence

Bearish events outweigh bullish events.

Sentiment

By Acuity

331 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Virbac SA

Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.
help-icon Live chat